Physician profile
Michael R Levine
NPI 1942375126
$3,544.83
in general payments reported to CMS, 2019-2025
33 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $271 · 2021: $565 · 2022: $640 · 2023: $604 · 2024: $311 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $421.15 | 2019-2022 | |
| Pfizer INC. | $317.18 | 2019-2025 | |
| Novo Nordisk INC | $235.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $232.57 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $219.65 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $132.69 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Lilly USA, LLC | $130.92 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $125.00 | 2023 | Erleada |
| Genzyme Corporation | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.85 | 2019-2025 | Jardiance |
| Allergan, INC. | $109.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.18 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $88.05 | 2021-2023 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $79.35 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $77.27 | 2021 | |
| Heartflow, INC. | $69.44 | 2023-2024 | Ffrct |
| Novartis Pharmaceuticals Corporation | $66.51 | 2019-2023 | |
| Astellas Pharma US INC | $52.77 | 2023-2024 | Veozah |
| Sanofi Pasteur INC. | $47.09 | 2023 | |
| Amarin Pharma, INC. | $46.34 | 2019 | |
| Amneal Pharmaceuticals LLC | $40.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.23 | 2021-2023 | Vpriv |
| Sumitomo Pharma America, INC. | $32.69 | 2025 | Myfembree |
| Medtronic USA, INC. | $26.66 | 2020 | |
| Circassia INC. | $17.35 | 2019 | |
| Horizon Therapeutics Plc | $16.92 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.97 | 2024 | |
| Bausch Health US, LLC | $15.27 | 2019 | |
| Almatica Pharma LLC | $13.91 | 2023 | Loreev Xr |
| Bavarian Nordic A/S | $13.48 | 2025 | Vivotif |
| Seqirus USA INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.